eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2013
vol. 30
 
Share:
Share:
abstract:

Review paper
Topical calcineurin inhibitors in dermatology. Part I: Properties, method and effectiveness of drug use

Katarzyna Gutfreund
,
Wojciech Bienias
,
Anna Szewczyk
,
Andrzej Kaszuba

Postep Derm Alergol 2013; XXX, 3: 165–169
Online publish date: 2013/06/20
View full text Get citation
 
Topical calcineurin inhibitors (TCI) are a relatively new class of drugs used in dermatology. There are two drug forms available – tacrolimus 0.03% or 0.1% ointment and 1.0% pimecrolimus cream. The drugs act by inhibiting synthesis of proinflammatory cytokines. The only approved indication for using TCI is treatment of atopic dermatitis. The TCI may be used as an alternative therapy to corticosteroids. Tacrolimus is used to treat moderate-to-severe atopic dermatitis, pimecrolimus – mild-to-moderate atopic dermatitis. Topical calcineurin inhibitors do not cause skin atrophy and the drug absorption through the skin is minimal. The TCI have been well-studied, their efficacy was evaluated in a number of vast, long-term studies. The anti-inflammatory potency of tacrolimus ointment is similar to a corticosteroid with moderate activity, while the latter is clearly more active than pimecrolimus cream. Topical calcineurin inhibitors significantly relieve pruritus in atopic eczema.
keywords:

topical calcineurin inhibitors, tacrolimus, pimecrolimus

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.